CRXTQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRXTQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Clarus Therapeutics Holdings is: No Data: Cannot be evaluated.
For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Clarus Therapeutics Holdings's Risk Assessment falls into.
Clarus Therapeutics Holdings (OTCPK:CRXTQ) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Mcnerney & Partners Lp | 10 percent owner | 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402 |
Kimberly M Murphy | director | 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
Elizabeth Cermak | director | 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517 |
Prygocki Mark A Sr | director | C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258 |
John Kenneth Amory | director | C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
Robert E. Dudley | director, officer: Chief Executive Officer | 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
Joseph Hernandez | director | C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
Richard D Peterson | officer: Chief Financial Officer | 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309 |
Frank Jaeger | officer: Chief Commercial Officer | CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662 |
Steven A. Bourne | officer: Chief Administrative Officer | 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062 |
Ffi Fund Ltd | 10 percent owner | DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208 |
Thomas, Mcnerney & Partners Ii L.p. | 10 percent owner | 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402 |
Thomas, Mcnerney & Partners Ii, Llc | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Tmp Nominee Ii, Llc | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Tmp Associates Ii Lp | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-17-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By GuruFocusNews GuruFocusNews • 06-07-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By GuruFocusNews GuruFocusNews • 05-29-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.